Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Metabolic and hormonal deregulations are both a risk factor and a hallmark of Alzheimer's disease (AD) and frontotemporal dementia (FTD), occurring early in the course of the disease. In FTD in particular, hyperorality and dietary changes are associated with metabolic and hormonal changes such as altered levels of the
| Condition(s) | Alzheimer Disease, Frontotemporal Dementia |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Metabolic and hormonal deregulations are both a risk factor and a hallmark of Alzheimer's disease (AD) and frontotemporal dementia (FTD), occurring early in the course of the disease. In FTD in particular, hyperorality and dietary changes are associated with metabolic and hormonal changes such as altered levels of the anorexigenic hormone leptin. The hypothalamus is a brain region that controls metabolism and hormonal systems. Hypothalamic function depends on its ability to sense peripheral signals. The hypothalamus sits on a circumventricular organ called the median eminence (ME) that puts it in contact with systemic blood circulation. In the ME, fenestrated capillaries allow the diffusion of bloodborne factors. However, despite the lack of blood-brain barrier at brain microvessels, diffu |
| Who can participate | Inclusion Criteria: * Subjects able to undergo a lumbar puncture * Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation To be assigned in the study subgroups, subjects will have to fulfill the specific following criteria: Group 1: Controls * absence of cognitive complaint (completion of the memory complaint questionnaire) * absence of significant cognitive impairment: normal MMSE according to age and education levels * Subjects capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information Group 2: Alzheimer's Disease * Diagnosis of probable Alzheimer's disease dementia according to the NIA 2011 criteria1 * MMSE ≥ 16 * Subjects who have |
| Ages | 40 Years to 85 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University Hospital, Lille |
| Locations | Lille, France |
| Start date | 2022-09-06 |
| NCT ID | NCT05288842 |
| Official listing | https://clinicaltrials.gov/study/NCT05288842 |